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Abstract We have previously shown that human immunodefi-
ciency virus (HIV)-1-tat induces the production of matrix
metalloproteinase-9 (MMP-9) in human monocytes by a
mechanism that is not understood. In the present report, we
demonstrate that HIV-tat-induced expression of MMP-9 is
blocked by inhibitors of protein tyrosine phosphatases
(PTPases). PTPase inhibitors also blocked HIV-tat-induced
nuclear transcription factor NF-UB activation and IUBK
degradation required for MMP-9 induction. These results
suggest that HIV-tat induces MMP-9 in human monocytes
through activation of PTPase and NF-UB.
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1. Introduction
Monocytes are major targets of human immunode¢ciency
virus-1 (HIV-1) infection and serve as a reservoir of viral
replication [1,2]. HIV infection enhances monocyte produc-
tion of IFN-Q, IL-1L, IL-6, GM-CSF, TNF and extracellular
matrix (ECM)-degrading metalloproteinases [3^7]. In addition
HIV-infected monocytes have a defect in the presentation of
antigen to CD4+ T cells [8]. Several e¡ects of HIV infection of
monocytes are mimicked by HIV-tat, a 76 aa protein of HIV
origin [9^11]. Exogenous HIV-tat acts as a potent transacti-
vator of HIV-1 long terminal repeat (LTR) and is essential for
the replication of the virus [12]. Recently we have shown that
treatment of monocytes with soluble HIV-tat protein enhan-
ces monocyte production of matrix metalloproteinases
(MMP-9) [9,10]. The MMPs compose a family of structurally
related endopeptidases that resorb macromolecules of the ex-
tracellular matrix. They are produced mainly by cells of the
myeloid lineage. Involved in normal tissue remodeling and
wound repair, in excess they may lead to connective tissue
damage and dysfunction [13,14]. Elevated MMP-9 production
contributes to the extravasation of HIV-infected monocytes
through vascular endothelium into the tissue in the early
stages of HIV disease [7,10,12]. However, the mechanism by
which HIV-tat induces the production of MMP-9 is not
known.
One possibility is through the nuclear transcription factor-
UB (NF-UB), a pleiotropic regulator of many genes involved
in immune and in£ammatory responses [15]. The activation of
NF-UB requires dissociation of a cytoplasmic heterodimer
consisting of p50 and p65 polypeptides from the inhibitory
subunit known as IUB. The dissociation of IUB is followed
by its degradation and the translocation of the p50-p65 het-
erodimer to the nucleus [16]. HIV-tat has been shown to acti-
vate NF-UB in some cell types [17], but whether it activates
NF-UB in monocytes and whether such activation leads to
MMP-9 production is not known. Further, although HIV-
tat has been reported to modulate the activity of several ki-
nases involved in signal transduction pathways, the role of
protein phosphatases (PPase) in HIV-tat-mediated cell signal-
ing has remained unclear. Using metabolic inhibitors of pro-
tein tyrosine phosphatases (PTPase), we have previously
shown that tumor necrosis factor (TNF)-induced cell surface
expression of adhesion molecules and NF-UB activation in
microvessel endothelial cells is regulated by PTPase [18,19].
In the present study we report that PTPase are also involved
in HIV-tat-mediated activation of NF-UB and MMP-9 pro-
duction.
2. Materials and methods
2.1. Materials
Penicillin, streptomycin, RPMI 1640 medium, and fetal bovine se-
rum were obtained from Gibco (Grand Island, NY). Glycine, NaCl,
and bovine serum albumin (BSA), diamide, and sodium orthovana-
date were obtained from Sigma Chemical Co. (Saint Louis, MO);
phenylarsinine oxide (PAO) was obtained from Aldrich Chemicals
(Milwaukee, WI). HIV-tat protein was obtained from the AIDS Re-
search and Reference Reagent Program of the National Institute of
Allergy and Infectious Diseases (Rockville, MD). U937 (a monocytic
cell line) cells were obtained from the American Type Culture Collec-
tion (Rockville, MD).
2.2. Detection of metalloproteinase in monocyte-conditioned medium
U937 were suspended at 106 cells/ml in RPMI containing 5% FBS
with or without HIV-tat protein for 24 h. The cells were then washed
in RPMI medium and resuspended at 1U106 cells/ml and incubated
for an additional 16 h. The cells were pelleted by centrifugation, and
the conditioned media collected for analysis by gelatin zymography
[10]. Aliquots of the conditioned media collected were mixed with
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sample bu¡er and subjected to electrophoresis using 10% polyacryl-
amide gel containing SDS and 1 mg/ml gelatin without prior heating
or reduction. The gels were incubated in 2.5% Triton X-100 for 1 h to
remove SDS and then incubated for 24 h in 50 mM Tris-HCl, pH 7.6,
50 mM NaCl, 5 mM CaCl2, and 0.02% NaN3. Finally, the gels were
stained for 60 min in 30% methanol, 10% acetic acid, and 0.5% Coo-
massie blue R-250, and then destained in distilled water.
2.3. Electrophoretic mobility shift assay (EMSA) for NF-UB
EMSAs were carried out as described in detail previously [18].
2.4. Western blotting for IUB
After the NF-UB activation reaction described above, postnuclear
extracts were resolved on 9% SDS-polyacrylamide gels, electrotrans-
ferred to nitrocellulose paper, probed with rabbit polyclonal antibody
against IUBK, and detected by chemiluminescence (ECL, Amersham
Corp.) [18].
3. Results and discussion
In this study we used inhibitors of protein tyrosine phos-
phatases to examine the role of protein tyrosine phosphor-
ylation in the HIV-tat-mediated induction of MMP-9 produc-
tion. For this study U937 cells were used because these
monocytic cells produce MMP-9 upon appropriate stimula-
tion [20,21]. The time of incubation and the concentrations
of HIV-tat and inhibitors used in this study had no e¡ect on
the viability of the cells (data not shown).
3.1. E¡ect of protein tyrosine phosphatase inhibitors on the
production of MMP-9 by U937 cells
In a recent report we showed that treatment of human
monocytes with HIV-tat protein resulted in a dose- and
time-dependent increase in the production of MMP-9 in the
cultures [10]. We used PAO, pervanadate (PV), and diamide
as PTPase inhibitors ([18] and references therein) and inves-
tigated their e¡ect on the production of MMP-9 in response
to HIV-tat. U937 cells were ¢rst pretreated with PAO, PV, or
diamide for 30 min and then with 100 ng/ml HIV-tat protein
at 37‡C for 24 h, followed by incubation of the cells for
another 18 h in medium. MMP-9 production was assayed as
described in Section 2. Treatment of U937 cells with HIV-tat
enhanced production of MMP-9 in the conditioned medium;
the increase in MMP-9 was completely blocked by PAO, PV,
and diamide. The inhibitors had no e¡ect on the production
of MMP-9 by cells that were not treated with HIV-tat (Fig.
1).
3.2. HIV-tat activates NF-UB in U937 cells
Because the promoter region of MMP-9 contains NF-UB
binding sites [22], we next investigated the e¡ect of HIV-tat
protein on the activation of NF-UB in U937 cells. The cells
were treated with 100 ng/ml HIV-tat for variable times and
NF-UB activation was measured. Maximum activation of NF-
UB was seen after 1 h of treatment with HIV-tat (Fig. 2A).
Treatment of cells with di¡erent concentrations of HIV-tat
protein for 1 h at 37‡C activated NF-UB in a dose-dependent
manner, reaching a maximum at a concentration of 100 ng/ml
(Fig. 2B).
To show that the retarded band observed by EMSA in
HIV-tat-treated cells was indeed NF-UB, nuclear extracts
were incubated with antibodies either to p50 (NF-UB1) or to
p65 (RelA) subunits. The antibodies to either subunit of NF-
UB shifted the band to a higher molecular weight (Fig. 2C),
thus suggesting the HIV-tat-activated complex consisted of
p50 and p65 units. Since only a partial shift of the NF-UB
band was observed with anti-p50 antibody, it is possible that
the NF-UB complex also consists of p52-p65 heterodimers.
Non-speci¢c antibody against cyclin D or preimmune serum
had no e¡ect on the mobility of NF-UB.
3.3. HIV-tat-induced activation of NF-UB involves the
degradation of IUBK
Activation of NF-UB by many agents requires dissociation
of inhibitory protein IUBK, which then undergoes proteolytic
degradation [15,16]. To determine the e¡ect of HIV-tat on the
cellular level of IUB, U937 cells were treated with 100 ng/ml of
HIV-tat protein for di¡erent times and the cytoplasmic ex-
tracts were examined by Western blot analysis using IUB-spe-
ci¢c antibodies. HIV-tat sharply decreased the level of IUB
after 45 min of treatment; the protein reappeared after 90
min, presumably because of NF-UB-dependent resynthesis
(Fig. 2D). These results thus show that the activation of
NF-UB by HIV-tat coincides with its e¡ect on the degradation
of IUB, the inhibitory protein.
3.4. Protein tyrosine phosphatase inhibitors block the
HIV-tat-induced activation of NF-UB
PAO has been shown to be a speci¢c inhibitor of PTPase.
As PAO was shown to block the production of MMP-9 by
U937 cells, we determined the e¡ect of PAO on HIV-tat-medi-
ated activation of NF-UB. The U937 cells were incubated with
di¡erent concentrations of PAO for 30 min and then treated
with HIV-tat (100 ng/ml) for 1 h; and activation of NF-UB
was checked. As shown in Fig. 3A, cotreatment of U937 cells
with PAO inhibited the activation of NF-UB in a dose-de-
pendent manner. The e¡ect of another inhibitor of PTPase,
PV, on HIV-tat-induced activation of NF-UB is shown in Fig.
3B. A 50 WM concentration of PV was su⁄cient to completely
inhibit the activation of NF-UB in response to HIV-tat. How-
ever, a slight activation of NF-UB was seen at 10 WM in this
and two other independent experiments (data not shown).
Fig. 1. E¡ects of PAO, PV and diamide on HIV-tat-induced pro-
duction of MMP-9 by U937 cells. U937 (1U106) cells were pre-
treated with or without PAO (2.4 WM), PV (50 WM), or diamide
(0.5 mM) for 30 min and then with 100 ng/ml HIV-tat protein or
treatment bu¡er alone for 18 h at 37‡C in a CO2 incubator. The
cells were washed and then incubated in serum-free RPMI medium
for an additional 16 h. The cells were then collected by centrifuga-
tion, and an aliquot of cell-free supernatant was subjected to elec-
trophoresis using 10% polyacrylamide gel containing SDS and 1 mg/
ml of gelatin. The gels were treated with 2.5% Triton X-100, devel-
oped for 24 h, and stained with Coomassie blue.
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Whether PTPase inhibitors block NF-UB activation by block-
ing HIV-tat-induced IUBK degradation was also examined. To
determine this U937 (1U106) cells were pretreated with PAO
for 30 min and then treated with 100 ng/ml HIV-tat protein
for di¡erent intervals of time, and the cytosolic extracts were
assayed for IUB by Western blot analysis. The results clearly
show that HIV-tat-induced degradation of IUBK is inhibited
by pretreatment of cells with PAO (Fig. 3C).
This is the ¢rst report to document the role of PTPase in
the production of MMP-9 by human monocytes in response
to HIV-tat protein. In another, earlier, report, we have shown
that PTPase plays an important role in the activation of NF-
UB by TNF [18]. Since the promoter region of the MMP-9
gene contains NF-UB binding sites [22], which play a critical
role in the expression of this gene, we investigated the e¡ects
of HIV-tat protein on the activation of NF-UB and its mod-
ulation by the inhibitors of PTPase in human monocytes. We
have recently shown that the expression of cell surface adhe-
sion molecules in human endothelial cells is regulated by a
similar mechanism [19] involving the activation of NF-UB. It
is therefore possible that HIV-tat treatment of cells induces a
signal transduction cascade that ultimately results in the acti-
vation of NF-UB and the expression of the plethora of genes
involved in in£ammatory responses. Indeed, HIV-tat has been
shown to upregulate the expression of several growth regula-
tory molecules such as lymphotoxin, TNF, interleukin-2,
transforming growth factor-L and major histocompatibilty
complex class I molecules, all of which have DNA binding
sequence for NF-UB near their promoter region [9^11,15].
Our results suggest that PTPase inhibitors suppress NF-UB
activation by blocking IUBK degradation. These results are
similar to that reported by us and others for abrogation of
TNF-induced NF-UB activation by PTPase inhibitors
[18,23,24]. PV is known to induce phosphorylation of tyrosine
residue 42 in IUBK which prevents its phosphorylation at ser-
ine 32 and 36 and subsequent degradation [23]. HIV-tat is
known to activate NF-UB in not only monocytes but also
non-monocyte cells [25^28]. The role of NF-UB in HIV-1
gene expression and replication has been well established.
NF-UB pathways play a central role in HIV-1 LTR-driven
transcription. The HIV-1 LTR contains two adjacent UB
binding sites in the enhancer region [29^31]. Transient trans-
Fig. 2. E¡ect of HIV-tat protein on activation of NF-UB. A: The cells were treated with 100 ng/ml HIV-tat protein for di¡erent intervals of
time at 37‡C. B: U937 (106) cells were treated with indicated concentrations of HIV-tat protein for 1 h. C: Nuclear extracts were prepared
from 100 ng/ml HIV-tat-treated U937 cells and incubated with di¡erent antibodies for 30 min at room temperature and then nuclear extracts
were assayed for NF-UB as described in Section 2. D: E¡ect of HIV-tat protein on degradation of IUB. U937 (106) cells were treated with
100 ng/ml HIV-tat protein for di¡erent intervals of time, and the cytosolic extracts were assayed for IUB by Western blot analysis as described
in Section 2.
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fection studies with HIV-1 LTR or HIV-1 enhancer reporter
constructs showed that HIV-1 gene expression increases upon
induction of NF-UB binding activity, and a mutation in the
NF-UB motif reduced gene expression in the presence or ab-
sence of di¡erent stimulators [32,33]. Since HIV-tat also in-
creases the activation of NF-UB and MMP-9, it may synerg-
istically contribute to the pathogenesis of HIV. Pathogenesis
could in turn be blocked by the inhibitors of PTPases.
Whether blockers of NF-UB activation modulate the HIV-
mediated pathogenesis remains to be established.
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